<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135900</url>
  </required_header>
  <id_info>
    <org_study_id>09-046</org_study_id>
    <nct_id>NCT02135900</nct_id>
  </id_info>
  <brief_title>The Use of Heliox in Obstructive Sleep Apnea Syndrome</brief_title>
  <acronym>HOSA</acronym>
  <official_title>The Use of Heliox in Obstructive Sleep Apnea Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Staten Island University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of the project is to evaluate the effects of Heliox therapy on obstructive sleep
      apnea syndrome (OSAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea syndrome (OSAS) is a common condition affecting up to 2-4 % of the
      general population. The pathophysiologic consequences of OSA include: excessive daytime
      sleepiness leading to increased car and work related accidents; and increased incidence of
      hypertension (HTN), stroke and possibly coronary artery events. In addition, patients with
      severe and untreated obstructive sleep apnea (OSA) have increased mortality compared to
      patients with treated severe OSA.The main stay of treatment of OSAS is the application of
      continuous positive airway pressure (CPAP) during sleep. The main problem with CPAP therapy
      is compliance. Heliox, a mixture of oxygen and helium has been used for many years in the
      treatment of upper airway obstruction. In this study, the investigators will evaluate the
      effectiveness of Heliox in the treatment of OSAS. Adult subjects with the diagnosis of
      obstructive sleep apnea syndrome who are referred for repeat sleep study for CPAP titration
      will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Apnea Hypopnea Index</measure>
    <time_frame>Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of Apnea/Hypopnea Index (AHI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apnea Index (AI)</measure>
    <time_frame>Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of Apnea Index (AI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lowest Oxygen Saturation (L SO2)</measure>
    <time_frame>Baseline and in 6-8 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of L SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Oxygen Saturation (M SO2)</measure>
    <time_frame>Baseline and in 6-8 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of M SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Heliox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heliox</intervention_name>
    <description>From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
    <arm_group_label>Heliox</arm_group_label>
    <other_name>Helium/Oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 or older with obstructive sleep apnea syndrome (OSAS) presenting for CPAP
             titration.

        Exclusion Criteria:

          -  Professional singers.

          -  Television or Radio hosts.

          -  Disk Jockeys.

          -  Subjects requiring oxygen therapy.

          -  Subjects younger than 18 year old.

          -  Pregnant women.

          -  Patients with chronic obstructive pulmonary disease (COPD) with forced expiratory
             volume 1 (FEV1) less than 50%.

          -  History of anatomic upper airway obstruction.

          -  Uncontrolled asthma.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Chalhoub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staten Island University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sleep center, Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 15, 2015</lastchanged_date>
  <firstreceived_date>July 4, 2012</firstreceived_date>
  <firstreceived_results_date>March 26, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Shore Long Island Jewish Health System</investigator_affiliation>
    <investigator_full_name>Michel Chalhoub</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heliox</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Heliox</title>
          <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">32 subjects started the study. 50 subjects were screened.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heliox</title>
          <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52" spread="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnea Hypopnea Index</title>
        <description>Assessment of Apnea/Hypopnea Index (AHI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
        <time_frame>Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects with documented sleep apnea syndrome on nocturnal polysomnography</population>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apnea Hypopnea Index</title>
            <description>Assessment of Apnea/Hypopnea Index (AHI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
            <units>Apneas or hypopneas per hour sleep</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At baseline ( without Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42.71" lower_limit="33.16" upper_limit="52.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>after 6-8 hours ( with Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.95" lower_limit="32.68" upper_limit="49.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apnea Index (AI)</title>
        <description>Assessment of Apnea Index (AI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
        <time_frame>Baseline and in 6-8 hours. The reported data are at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects with documented sleep apnea syndrome on nocturnal polysomnography</population>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apnea Index (AI)</title>
            <description>Assessment of Apnea Index (AI) at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
            <units>Number of apneas per hour sleep</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At baseline ( without Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.46" lower_limit="7.59" upper_limit="25.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>after 6-8 hours ( with Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.26" lower_limit="4.98" upper_limit="17.53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lowest Oxygen Saturation (L SO2)</title>
        <description>Assessment of L SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
        <time_frame>Baseline and in 6-8 hours.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects with documented sleep apnea syndrome on nocturnal polysomnography</population>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Lowest Oxygen Saturation (L SO2)</title>
            <description>Assessment of L SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
            <units>Percentage of oxygen saturation</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At baseline ( without Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84.22" lower_limit="82.07" upper_limit="86.38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>after 6-8 hours ( with Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.47" lower_limit="88.71" upper_limit="92.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Oxygen Saturation (M SO2)</title>
        <description>Assessment of M SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
        <time_frame>Baseline and in 6-8 hours.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects with documented sleep apnea syndrome on nocturnal polysomnography</population>
        <group_list>
          <group group_id="O1">
            <title>Heliox</title>
            <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Oxygen Saturation (M SO2)</title>
            <description>Assessment of M SO2 at baseline ( without heliox) and after 6-8 hours of sleep with heliox.</description>
            <units>Percentage of oxygen saturation</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>At baseline ( without Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.47" lower_limit="92.50" upper_limit="94.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>after 6-8 hours ( with Heliox)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.29" lower_limit="95.51" upper_limit="97.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Heliox</title>
          <description>Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
Heliox: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michel Chalhoub, MD</name_or_title>
      <organization>Staten Island University Hospital</organization>
      <phone>7182269000</phone>
      <email>chalhoubmichel@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
